Kendle targets Asia with further Indian expansion

By Nick Taylor

- Last updated on GMT

Related tags India Clinical trial

Kendle is continuing its efforts to increase its presence outside the US with the establishment of a second office in Ahmedabad in Western India.

The company has had a presence in New Delhi, India since 2004 and has been expanding to allow its clients increased access to the nation’s favourable research conditions.

Asia/Pacific has been targeted by the company as a region that will help it maintain its impressive organic growth in a difficult operating environment.

Candace Kendle, PharmD, Chairman and CEO, said: "Expansion in the Asia/Pacific region, and India in particular, is essential to our continued success as a top global CRO​.

Our increased presence and capacity in the region will allow us to better meet the needs of our customers who are seeking to capitalise on India's cost-effective, yet high-quality clinical research capabilities to develop their compounds​."

By continuing to expand outside of its regional base in New Delhi Kendle has given itself access to a greater proportion of the Indian population, which is one of the big attractions to companies looking to conduct trials in the country.

In addition to easing the recruitment of patients for clinical trials having access to a broad geographic area gives Kendle access to more of the talent pools spread around India.

Ahmedabad has become a focal point for the Indian pharmaceutical industry and multi-nationals looking to set up in the country.

This has been underpinned by the presence of renowned scientific education establishments and Zydus Cadila and Torrent Pharmaceuticals establishing their headquarters in the city.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more